Callan Family Office LLC Invests $566,000 in Prestige Consumer Healthcare Inc. $PBH

Key Points

• Callan Family Office LLC has made a newly acquired investment of $566,000 in Prestige Consumer Healthcare Inc. by purchasing 7,083 shares in the second quarter.
• Despite recent analyst upgrades, the company reported lower-than-expected earnings of $0.95 per share, missing estimates of $1.01, and a revenue decline of 6.6% year-over-year.
• The current market cap for Prestige Consumer Healthcare Inc. is $3.05 billion, and analysts have a consensus target price of $94.80 on the stock, with ratings ranging from "Buy" to "Sell".

Callan Family Office LLC purchased a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 7,083 shares of the company's stock, valued at approximately $566,000.

A number of other hedge funds and other institutional investors have also modified their holdings of PBH. UMB Bank n.a. grew its holdings in shares of Prestige Consumer Healthcare by 81.8% during the second quarter. UMB Bank n.a. now owns 320 shares of the company's stock worth $26,000 after buying an additional 144 shares in the last quarter. Maseco LLP purchased a new stake in shares of Prestige Consumer Healthcare during the second quarter worth about $27,000. Opal Wealth Advisors LLC purchased a new stake in shares of Prestige Consumer Healthcare during the first quarter worth about $38,000. Geneos Wealth Management Inc. grew its holdings in shares of Prestige Consumer Healthcare by 92.8% during the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock worth $48,000 after buying an additional 269 shares in the last quarter. Finally, Costello Asset Management INC purchased a new stake in shares of Prestige Consumer Healthcare during the first quarter worth about $112,000. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Trading Up 0.1%

Shares of PBH stock opened at $61.93 on Wednesday. The stock has a market cap of $3.05 billion, a price-to-earnings ratio of 14.54, a price-to-earnings-growth ratio of 1.95 and a beta of 0.44. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55. Prestige Consumer Healthcare Inc. has a fifty-two week low of $60.15 and a fifty-two week high of $90.04. The firm's 50 day moving average price is $64.78 and its two-hundred day moving average price is $75.81.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). The business had revenue of $249.53 million for the quarter, compared to analyst estimates of $260.71 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The company's quarterly revenue was down 6.6% on a year-over-year basis. During the same period last year, the firm earned $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. On average, analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on PBH shares. Sidoti upgraded shares of Prestige Consumer Healthcare from a "neutral" rating to a "buy" rating and set a $80.00 price target for the company in a report on Wednesday, September 24th. Canaccord Genuity Group lowered their target price on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a report on Friday, August 8th. Wall Street Zen downgraded shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Zacks Research downgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a report on Thursday, September 4th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Prestige Consumer Healthcare in a report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $94.80.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.